BFBIO

⚡ Flash Summary

BF Biosciences Limited (BFBIO) reported strong revenue growth of 60% for the year ended June 30, 2025, reaching Rs. 5,837 million compared to Rs. 3,659 million in the previous year. This growth was driven by both in-market generic sales (50% increase) and institutional sales (127% increase), mainly from new products and Line II operations. However, the gross profit margin decreased to 39% due to increased factory overheads from Line II commissioning. The company also increased selling and distribution expenses by 102% to support top-line growth, resulting in an EPS of Rs. 5.52 per share, a decrease from the previous year due to an increase in the weighted average number of shares after the IPO.

📌 Key Takeaways

• 🚀 Revenue jumped by 60%, from Rs. 3,659 million to Rs. 5,837 million, driven by generics and institutional sales.
• 💊 In-market generic sales grew by 50%.
• 🏥 Institutional sales skyrocketed by 127%.
• 🏭 New products and Line II operations fueled sales increase.
• 📉 Gross profit margin decreased to 39% due to factory overhead increases.
• 💸 Selling and distribution expenses surged by 102% to support topline growth.
• 📉 EPS declined to Rs. 5.52 due to increased weighted average number of shares after IPO.
• 💰 Profit after tax increased by 16%, from Rs. 385 million to Rs. 447 million.
• 🔬 R&D investment continues to be a priority to support future growth.
• 🏭 Line II expansion completed, poised to contribute to future production capacity.
• 🚫 No cash dividend recommended to ensure long-term business sustainability.
• 🤝 Collaborations with Gilead and other partners remain crucial for product access.
• 🚺 Three female directors present on the seven-member Board, demonstrating diversity.

🎯 Investment Thesis

Hold the current position. While revenue growth is strong, the dip in EPS warrants further investigation. Further monitoring of cost management and factory overheads, and the effective execution of sales plans, must continue. A more detailed valuation is not possible with the information available.

⚡ Flash Summary

BF Biosciences Limited (BFBIO) has announced its Annual General Meeting (AGM) to be held on October 25, 2025, in Rawalpindi and via video-link. Key agenda items include confirming the minutes of the previous AGM, receiving and adopting the audited financial statements for the year ended June 30, 2025, and appointing auditors for the year ending June 30, 2026. A significant item for shareholders’ consideration is the approval of related party transactions conducted during the financial year 2024-25 and authorization for the Board to approve future related party transactions. The company encourages electronic dividend mandates and submission of CNICs to ensure compliance with regulations and avoid withholding tax issues.

📌 Key Takeaways

• 📅 AGM Date: October 25, 2025, at 12:15 P.M.
• 📍 Location: Blue Lagoon, Masood Akhter Kiani Road, Rawalpindi, and via video-link.
• ✅ Confirmation: Approval of minutes from the AGM held on October 28, 2024.
• 🧾 Financials: Review and adoption of audited financial statements for the year ended June 30, 2025.
• 🧑‍💼 Auditor Appointment: Appointment of auditors for the year ending June 30, 2026.
• 🤝 Related Party Transactions: Approval of related party transactions conducted during FY 2024-25.
• 📜 Special Resolutions: Authorization for Board to approve future related party transactions.
• 🏦 Book Closure: Share transfer books closed from October 18, 2025, to October 25, 2025.
• 🗳️ Proxy Voting: Members can appoint a proxy; proxy form available on the company website.
• 💻 Video Link: Shareholders can participate via video link by registering and emailing required details by sending email to cs@bfbio.com.
• 🆔 CNIC Submission: Members requested to submit CNIC copies to update records.
• 💳 Electronic Dividend Mandate: Encouraged for direct bank transfers of dividends.
• Tax: Withholding tax on dividends at 15% for active taxpayers and 30% for non-active taxpayers.
• ✉️ Postal Ballot: Members can vote on special business items via postal ballot, with specific deadlines.
• 🌐 Website: Financial statements available on the company website www.bfbio.com.

🎯 Investment Thesis

Based on the AGM notice alone, a HOLD recommendation is appropriate. The notice primarily covers procedural matters and does not provide enough information to assess the company’s financial health or growth prospects. The focus on related party transactions suggests a need for careful monitoring of governance practices. A more informed investment decision would require a thorough review of the company’s financial statements and performance indicators. Price target cannot be determined.